Image
A Phone-a-Friend Peer Consult Series™

Answers to Everyday Practice Challenges in HIV Medicine

Suggested Readings

The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature.

Carvalho AF, Sharma MS, Brunoni AR, et al. Psychother Psychosom. 2016;85(5):270-288.

Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.

Ciaffi L, Koulla-Shiro S, Sawadogo AB, et al. Lancet HIV. 2017;4(9):e384-e392.

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.

Cutrell AG, Schapiro JM, Perno CF, et al. AIDS. 2021;35(9):1333–1342.

Use of Injectable CAB/RPV LA as Replacement ART in Virally Suppressed Adults With HIV.

DeHaan E, McGowan JP, Fine SM, et al, for the Medical Care Criteria Committee of the New York State Department of Health AIDS Institute. Baltimore, MD: Johns Hopkins University; 2021.

Phase 3 study of ibalizumab for multidrug-resistant HIV-1.

Emu B, Fessel J, Schrader S, et al. N Engl J Med. 2018;379(7):645-654.

Cabotegravir and rilpivirine PK following long-acting HIV treatment discontinuation.

Ford S, Crauwels H, Han K, et al. CROI. Virtual Conference; March 8-11, 2020. Abstract 466.

Switching to bictegravir/emtricitabine/tenofovir alafenamide in Black Americans with HIV-1: a randomized phase 3b, multicenter, open-label study.

Hagins D, Kumar P, Saag M, et al. J Acquir Immune Defic Syndr. 2021;88(1):86-95.

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients.

Hoffmann C, Welz T, Sabranski M, et al. HIV Med. 2017;18(1):56-63.

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.

Lataillade M, Lalezari JP, Kozal M, et al. Lancet HIV. 2020;7(11):e740-e751.

Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.

Lockman S, Brummel SS, Ziemba L, et al. Lancet. 2021;397(10281):1276-1292.

Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection.

Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. N Engl J Med. 2020;382(12):1124-1135.

Depression and anxiety disorders: benefits of exercise, yoga, and meditation.

Saeed SA, Cunningham K, Bloch RM. Am Fam Physician. 2019;99(10):620-627.

Potent antiviral activity of lenacapavir in phase 2/3 in heavily ART-experienced PWH.

Segal-Maurer S, Castagna A, Berhe M, et al.  CROI. Virtual Conference; March 6-10, 2021. Abstract 127.

Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression.

Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. N Engl J Med. 2020;382(12):1112-1123.

Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana.

Zash R, Holmes L, Diseko M, et al. J Int AIDS Soc. 2020;23(suppl 4):185-186.

Activity
Long-Acting Injectables

Module 1

Activity
Adolescents and Young Adults Newly Diagnosed with HIV

Module 2

Activity
HIV in Women

Module 3

Activity
Heavily Treatment-Experienced Patients

Module 4

Activity
Controversies in Managing Resistance

Module 5

Activity
Neuropsychological and Cognitive Changes

Module 6

Activity
Substance Use Disorder

Module 7

Relevant Resources

PrEP for Your Patients’ Needs

The PCPs Role in Preventing HIV

Value-Based HIV Formularies

Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care

Hepatitis C is Curable

Got it? Treat it!

Real-World Issues in HIV Prevention & Treatment

The Critical Role of the Community Pharmacist

BLOCK HIV/HCV

Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.

Evolving Models of HIV Care

Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box

Updates in HCV Screening and Treatment

Key Issues Impacting OB/GYN Practice

Clinical Issues in Chronic Liver Disease

Hot Topics in HBV, HCV, and NASH

Evolving Models of HIV Care

Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice

Assessing Your Patients for HCV and HIV

Why It Matters in OB/GYN Practice Today

HIV as a Chronic Disease

A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities

The Pursuit of Hepatitis C Elimination

How the Pharmacist Can Make a Difference

Trends in Infectious Diseases: Updates on Treatment & Prevention Strategies for HIV and HCV

Understanding the Growing Syndemic — Opioids, HCV, and HIV

Stepping Up to the Challenge

The PCP’s Role in HCV Elimination

The Changing Landscape of HIV Prevention

What the Pharmacist Needs to Know about PrEP

Evolving Models of HIV Care (Volume 3)

The Rapid ART Standard of Care: From Evidence to Healthcare Equity

HIV Updates for Pharmacy Practice

Maximizing Your Role to Impact Patient Outcomes

BRIDGE HCV

Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV

Case Challenges in HIV Medicine

Benefits, Barriers, & Best Practices in an Advancing Field

Challenges and Opportunities in HIV

Practical Solutions Across the Spectrum of Care

Expanding HIV Prevention in Colorado—and Nationwide

A PEP/PrEP Training Guide for Pharmacists

Treating Hepatitis C in the Primary Care Setting

A Critical Step Toward HCV Elimination

Honing Clinical Skills in HIV Treatment

Considering the Patient, the Provider, and the Science

Hot Topics in HCV

A Multidisciplinary Online Mini-Curriculum

Clinical Issues in COVID-19

Debates and Discussions about Monoclonal Antibody Therapies

Minimizing Patient Risks From COVID-19

An Update on Monoclonal Antibody Therapies

Treating Hepatitis C in the Primary Care Setting

Establishing Clinical Readiness Through Mentored Learning